

Medigen Biotechnology Corp. (3176 MEDIGEN)					
SEQ_NO	2	Date of announcement	2023/06/06	Time of announcement	17:03:00
Subject	Results of Phase II clinical trial of OBP-301 presented at the American Society of Clinical Oncology (ASCO)				
Date of events	2023/06/06	To which item it meets	Paragraph 53		
Statement	<p>1. Date of occurrence of the event: 2023/06/06</p> <p>2. Company name: Medigen Biotechnology Corp.</p> <p>3. Relationship to the Company (please enter "head office" or "subsidiaries"): head office</p> <p>4. Reciprocal shareholding ratios: N/A</p> <p>5. Cause of occurrence: Medigen Biotechnology Corp. and the Japanese publicly traded company Oncolys BioPharma (TSE stock code 4588) are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys announced today (June 6, 2023), that the results of a Phase II clinical trial of OBP-301 combined with an immune checkpoint inhibitor initiated by the principal investigator in the United States for the treatment of gastric cancer and gastroesophageal junction cancer were presented at this year's Annual Meeting of the American Society of Clinical Oncology (ASCO). The purpose of this trial was to investigate the efficacy, safety, and immunogenicity profile of OBP-301 in combination with the PD-1 antibody drug (pembrolizumab) in severely stage IV patients. Among the 16 subjects, 2 cases showed partial response (PR), and these 2 subjects currently have no evidence of disease (NED). Regarding safety, good tolerance was confirmed.</p> <p>6. Countermeasures: none</p> <p>7. Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):</p> <p>(1) Explanation of the subsequent clinical development progress as an update of the announcement made on December 19, 2022.</p>				

(2) New drug development involves lengthy timelines, high costs, and success is not guaranteed. Such factors introduce risks to investments, and investors should exercise caution and careful judgment when considering investments.

(3) Medigen shares the research and development costs of OBP-301 with Oncolys BioPharma, and will also share future commercial benefits.

(3) Link to the announcement by Oncolys BioPharma in Japan:

<https://ssl4.eir-parts.net/doc/4588/tdnet/2295642/00.pdf>

